Dexa-BEAM is not Effective in Patients with Relapsed or Resistant Aggressive High-Grade Non-Hodgkin's Lymphoma

References

• Fischer R. I., Gaynor E. R., Dahlberg S., Oken M. M., Grogan T. M., Mize E. M., Glick J. H., Coltman C. A., jr., Miller T. P. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non‐Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–6
   PubMed Web of Science ®Google Scholar
• Gaidano G., Dalla F. Lymphomas. Cancer: Principles & Practice of OncologyFifth Edition, V. T. de Vita, S. H. Hellmann, S. A. Rosenberg. Lippincott‐Raven Publishers, Philadelphia 1997; 261–297
   Google Scholar
• Ho A. D., Del Valle F., Rückle H., Schwammborn J., Schlimok G., Hiddemann W., Meusers P., Thiel E., Dörken B., Hunstein W. Mitoxantrone and high‐dose cytara‐bine as salvage therapy for refractory Non‐Hodgkin's lymphoma. Cancer 1989; 64: 1388–1392
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeister F. B., McLaughlin P., Velasquez W. S., Riggs S., Fuller L., Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal of Clinical Oncology 1987; 5: 407–412
   PubMed Web of Science ®Google Scholar
• Haim N., Rosenblatt E., Wollner M., Ben‐Shahar M., Epel‐baum R., Robinson E. Salvage therapy for Non‐Hodgkin's lymphoma with a combination of dexam‐ethasone, etoposide, ifosfamide, and cisplatin. Cancer Chemother Pharmacol 1992; 30: 243–244
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabanillas E., Salvador P. Effective salvage therapy for lymphoma wih cisplatin in combination with high‐dose Ara‐C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Goss P. E., Shephard F. A., Scott J. G. Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory Non‐Hodgkin's lymphoma Preliminary report of a Phase II study. Annals of Oncology 1991; 2: 43–46
   PubMed Web of Science ®Google Scholar
• Cabanillas E., Hagemeister F. B., Bodley G. P., Freireich E. J. IMVP‐16 An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697
   PubMed Web of Science ®Google Scholar
• Engert A., Schnell R., Küpper F., Reiser M., Engelhard M., Wilhelm M., Lathan B., Baltes‐Engler S., Winterhalter B., Scheulen M. E., Dederichs B., Tesch H., Wörmann B., Diehl V. A phase‐I study with idarubicin, ifosfamide and VP‐16 (IIVP‐16) in patients with refractory or relapsed high‐grade non‐Hodgkin's lymphoma. Leukemia and Lymphoma 1997; 24: 513–522
   PubMed Web of Science ®Google Scholar
• Reiser M., Schnell R., Straub G., Wilhelm M., Übelacker R., Wörmann B., Münch R., Diehl V., Engert A. DIZE (Dexam‐ethasone, Idarubicin, and continuous infusion of ifosfamide and etoposide) An effective and well‐tolerated new regimen for patients with relapsed lymphoma. Leukemia and Lymphoma 1998; 31: 359–366
   PubMed Web of Science ®Google Scholar
• Shipp M. A., Yeap B. Y., Harrington D. The m‐BACOD combination chemotherapy regimen in large‐cell lymphoma: Analysis of the completed trial and comparison with the M‐BACOD regimen. Journal of Clinical Oncology 1990; 8: 8493
   Google Scholar
• Peterson E., Appelbaum E., Hill R. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. Journal of Clinical Oncology 1990; 8: 638–647
   PubMed Web of Science ®Google Scholar
• Verdonck L. E., Dekker A. W., De Gast G. C., van Kempen M. L., Lokhorst H. M., Nieuwenhuis H. K. Salvage therapy with ProMACE‐MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with Non‐Hodgkin's lymphoma who failed to respond to first line CHOP. Journal of Clinical Oncology 1992; 12: 1949–1954
   Google Scholar
• Bosley A., Coiffer B., Gisselbrecht C., Tilly H., Auzanneau G., Andrien E., Herbrecht R., Legros M., Devaux Y., Jaubert J., Pignon B., Michaux J. L., Humblet Y., Dupriez B., Thyss A., Lederlin P. Bone marrow transplantation prolongs survival after relapse in aggressive‐lymphoma patients treated with the LNH‐84 regimen. Journal of Clinical Oncology 1992; 10: 1615–1623
   PubMed Web of Science ®Google Scholar
• Philip T., Guglielmi C., Hagenbeek A., Somers R., van der Lelie H., Bron D., Sonnefael P., Gisselbrecht C., Conn J. Y., Harousseau J. L., Coiffier B., Brion P., Mandelli F., Chauvin F. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy‐sensitive NHL. New England Journal of Medince 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M. G., Rueffer U., Lathan B., Schmitz N., Broesteanu O., Hasenclever D., Haas R., Kirchner H., Koch P., Kruse R., Loeffler M., Diehl V. Dexa‐BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens A trial of the German Hodgkin's Disease Study Group. Journal of Clinical Oncology 1994; 12: 580–586
   PubMed Web of Science ®Google Scholar
• Josting A., Kàtay I., Rueffer U., Winter S., Tesch H., Engert A., Diehl V., Wickramanayake P. D. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high‐dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa‐BEAM). Annals of Oncology 1998; 9: 289–295
   PubMed Web of Science ®Google Scholar
• Williams S. F. The role of bone marrow transplantation in the Non‐Hodgkin's lymphomas. Seminars in Oncology 1990; 17: 88–95
   PubMed Web of Science ®Google Scholar
• Philip T., Armitage J. O., Spitzer G., Chauvin R., Jagannath S., Cahn J. Y., Colombat P., Goldstone A. H., Gorin N., Flesh M., Laporte J. P., Maraninchi D., Pico J., Bosley A., Anderson C., Schots R., Biron P., Cabanillas E., Dicke K. High‐dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate‐grade or high‐grade lymphoma. New England Journal of Medicine 1987; 24: 1493–1498
   Web of Science ®Google Scholar
• Freedman A. S., Takvorian T., Anderson K. C., Mauch P., Rabinowe S. N., Blake K., Yeap B., Soiffer R., Coral E., Hef‐lin L., Ritz J., Nadler L. M. Autologous bone marrow transplantation in B‐cell Non‐Hodgkin's lymphoma: Very low treatment‐related mortality in 100 patients in sensitive relapse. Journal of Clinical Oncology 1987; 8: 784–791
   Google Scholar
• Gulati S., Yahalom J., Acaba L., Reich L., Motzer R., Crown J., Toia M., Igarashi T., Lemoli R., Hanninen E., Doherty M. Treatment of patients with relapsed and resistant Non‐Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. Journal of Clinical Oncology 1992; 10: 936–941
   PubMed Web of Science ®Google Scholar
• Schmitz N., Sextro M., Hasenclever D., Carella A., Fiedler R., Schlimok G., Hossfeld D. K., Diehl V. HD‐R1 first results of a randomized trial comparing aggressive chemotherapy with high‐dose therapy and hematopoietic stem cell transplantation in patients with chemosensitive relapse of Hodgkin's disease. Blood 1997; 10: 499, (Suppll)(abstract)
   Google Scholar
• Press O. W., Livingston R., Mortimer J., Collins C., Appelbaum R. Treatment of relapsed NHL with dexametha‐sone, high‐dose cytarabine and cisplatin before marrow transplantation. Journal of Clinical Oncology 1991; 9: 423–431
   PubMed Web of Science ®Google Scholar
• Engert A., Josting A., Mapara M., Dörken B., Draube A., Re D., Borchmann P., Scheid C., Tesch H., Wolf J., Diehl V. High‐dose sequential chemotherapy and autologous stem cell support for relapsed or refractory Hodgkin's and Non‐Hodgkin's lymphoma‐first results from an ongoing multicenter pilot study. Leukemia and Lymphoma 1998; 29: P‐152, abstract
   Google Scholar